Vivoryon Therapeutics N.V. (0R3M.L)

EUR 1.66

(-2.24%)

Net Income Summary of Vivoryon Therapeutics N.V.

Vivoryon Therapeutics N.V.'s latest annual net income in 2023 was -28.34 Million EUR , down -0.66% from previous year.
Vivoryon Therapeutics N.V.'s latest quarterly net income in 2024 Q2 was -13.55 Million EUR , down 0.0% from previous quarter.
Vivoryon Therapeutics N.V. reported an annual net income of -28.15 Million EUR in 2022, down -122.49% from previous year.
Vivoryon Therapeutics N.V. reported an annual net income of -12.65 Million EUR in 2021, up 23.35% from previous year.
Vivoryon Therapeutics N.V. reported a quarterly net income of -10.71 Million EUR for 2023 Q2, down 0.0% from previous quarter.
Vivoryon Therapeutics N.V. reported a quarterly net income of -28.34 Million EUR for 2023 FY, down -0.66% from previous quarter.

Annual Net Income Chart of Vivoryon Therapeutics N.V. (2023 - 2011)

Historical Annual Net Income of Vivoryon Therapeutics N.V. (2023 - 2011)

Year	Net Income	Net Income Growth
2023	-28.34 Million EUR	-0.66%
2022	-28.15 Million EUR	-122.49%
2021	-12.65 Million EUR	23.35%
2020	-16.51 Million EUR	-111.04%
2019	-7.82 Million EUR	-1.11%
2018	-7.73 Million EUR	3.4%
2017	-8 Million EUR	42.34%
2016	-13.89 Million EUR	-2.86%
2015	-13.5 Million EUR	-18.08%
2014	-11.43 Million EUR	-15.19%
2013	-9.92 Million EUR	46.96%
2012	-18.72 Million EUR	-14.8%
2011	-16.3 Million EUR	0.0%

Year	Net Income	Net Income Growth
2024 Q2	-13.55 Million EUR	0.0%
2023 Q2	-10.71 Million EUR	0.0%
2023 FY	-28.34 Million EUR	-0.66%
2023 Q4	-17.62 Million EUR	0.0%
2022 FY	-28.15 Million EUR	-122.49%
2022 Q2	-12.58 Million EUR	0.0%
2022 Q4	-15.57 Million EUR	0.0%
2021 Q4	-984 Thousand EUR	0.0%
2021 Q2	-11.67 Million EUR	0.0%
2021 FY	-12.65 Million EUR	23.35%
2020 FY	-16.51 Million EUR	-111.04%
2020 Q4	-8.93 Million EUR	0.0%
2020 Q2	-7.57 Million EUR	0.0%
2019 Q4	-4.73 Million EUR	0.0%
2019 FY	-7.82 Million EUR	-1.11%
2019 Q2	-3.09 Million EUR	0.0%
2018 Q2	-4.12 Million EUR	0.0%
2018 Q4	-3.61 Million EUR	0.0%
2018 FY	-7.73 Million EUR	3.4%
2017 Q2	-4.3 Million EUR	0.0%
2017 FY	-8 Million EUR	42.34%
2017 Q4	-3.7 Million EUR	0.0%
2016 FY	-13.89 Million EUR	-2.86%
2016 Q4	-7.84 Million EUR	0.0%
2016 Q2	-6.04 Million EUR	0.0%
2015 FY	-13.5 Million EUR	-18.08%
2015 Q2	-6.23 Million EUR	0.0%
2015 Q4	-7.27 Million EUR	0.0%
2014 Q2	-3.79 Million EUR	0.0%
2014 FY	-11.43 Million EUR	-15.19%
2014 Q4	-7.64 Million EUR	0.0%
2013 Q4	-4.94 Million EUR	-100.28%
2013 FY	-9.92 Million EUR	46.96%
2013 Q3	-2.46 Million EUR	48.73%
2013 Q2	-4.81 Million EUR	-95.06%
2013 Q1	-2.46 Million EUR	0.0%
2012 Q1	-2.88 Million EUR	0.0%
2012 Q3	-2.88 Million EUR	0.0%
2012 Q4	-2.46 Million EUR	14.37%
2012 FY	-18.72 Million EUR	-14.8%
2012 Q2	-2.88 Million EUR	0.0%
2011 Q4	-2.88 Million EUR	19.13%
2011 Q1	-3.56 Million EUR	0.0%
2011 Q3	-3.56 Million EUR	0.0%
2011 Q2	-3.56 Million EUR	0.0%
2011 FY	-16.3 Million EUR	0.0%
2010 Q4	-3.56 Million EUR	0.0%

Peer Net Income Comparison of Vivoryon Therapeutics N.V.

Name	Net Income	Net Income Difference
Boiron SA	35.82 Million EUR	179.108%
Laboratorios Farmaceuticos Rovi, S.A.	170.33 Million EUR	116.639%
Vetoquinol SA	55.56 Million EUR	151.012%
Valneva SE	-101.42 Million EUR	72.057%
AB Science S.A.	-10.04 Million EUR	-182.066%
Nanobiotix S.A.	-39.7 Million EUR	28.61%
PHAXIAM Therapeutics S.A.	-23.48 Million EUR	-20.666%
BioSenic S.A.	-28.77 Million EUR	1.515%
ABIVAX Société Anonyme	-147.74 Million EUR	80.816%
Formycon AG	75.79 Million EUR	137.393%